415 related articles for article (PubMed ID: 24029591)
21. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
22. Role of lymphangiogenic factors in tumor metastasis.
He Y; Karpanen T; Alitalo K
Biochim Biophys Acta; 2004 Mar; 1654(1):3-12. PubMed ID: 14984763
[TBL] [Abstract][Full Text] [Related]
23. Lymphangiogenesis of normal endometrium and endometrial adenocarcinoma.
Donoghue JF; Lederman FL; Susil BJ; Rogers PA
Hum Reprod; 2007 Jun; 22(6):1705-13. PubMed ID: 17347164
[TBL] [Abstract][Full Text] [Related]
24. Gingival lymphatic drainage protects against Porphyromonas gingivalis-induced bone loss in mice.
Mkonyi LE; Bletsa A; Bolstad AI; Bakken V; Wiig H; Berggreen E
Am J Pathol; 2012 Sep; 181(3):907-16. PubMed ID: 22901755
[TBL] [Abstract][Full Text] [Related]
25. Lymphangiogenesis in the bone-implant interface of orthopedic implants: importance and consequence.
Jell G; Kerjaschki D; Revell P; Al-Saffar N
J Biomed Mater Res A; 2006 Apr; 77(1):119-27. PubMed ID: 16392126
[TBL] [Abstract][Full Text] [Related]
26. VEGFR signaling during lymphatic vascular development: From progenitor cells to functional vessels.
Secker GA; Harvey NL
Dev Dyn; 2015 Mar; 244(3):323-31. PubMed ID: 25399804
[TBL] [Abstract][Full Text] [Related]
27. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
Jeon BH; Jang C; Han J; Kataru RP; Piao L; Jung K; Cha HJ; Schwendener RA; Jang KY; Kim KS; Alitalo K; Koh GY
Cancer Res; 2008 Feb; 68(4):1100-9. PubMed ID: 18281485
[TBL] [Abstract][Full Text] [Related]
28. [Lymphangiogenesis and tumor progression].
Vittet D; Feige JJ
Bull Cancer; 2007 Oct; 94(10):881-6. PubMed ID: 17964982
[TBL] [Abstract][Full Text] [Related]
29. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis.
Wong SY; Haack H; Crowley D; Barry M; Bronson RT; Hynes RO
Cancer Res; 2005 Nov; 65(21):9789-98. PubMed ID: 16267000
[TBL] [Abstract][Full Text] [Related]
30. Tumor-induced lymphangiogenesis: a target for cancer therapy?
Thiele W; Sleeman JP
J Biotechnol; 2006 Jun; 124(1):224-41. PubMed ID: 16497404
[TBL] [Abstract][Full Text] [Related]
31. Molecular targeting of lymphatics for therapy.
Stacker SA; Hughes RA; Achen MG
Curr Pharm Des; 2004; 10(1):65-74. PubMed ID: 14754406
[TBL] [Abstract][Full Text] [Related]
32. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
[TBL] [Abstract][Full Text] [Related]
33. Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis.
Honda N; Jinnin M; Kajihara I; Makino T; Fukushima S; Ihn H
Br J Dermatol; 2010 Oct; 163(4):776-80. PubMed ID: 20491763
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous characteristics of lymphatic microvasculatures associated with pulmonary sarcoid granulomas.
Yamashita M; Mouri T; Niisato M; Kowada K; Kobayashi H; Chiba R; Satoh T; Sugai T; Sawai T; Takahashi T; Yamauchi K
Ann Am Thorac Soc; 2013 Apr; 10(2):90-7. PubMed ID: 23607836
[TBL] [Abstract][Full Text] [Related]
35. A system for quantifying the patterning of the lymphatic vasculature.
Shayan R; Karnezis T; Tsantikos E; Williams SP; Runting AS; Ashton MW; Achen MG; Hibbs ML; Stacker SA
Growth Factors; 2007 Dec; 25(6):417-25. PubMed ID: 18365872
[TBL] [Abstract][Full Text] [Related]
36. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.
Mäkinen T; Jussila L; Veikkola T; Karpanen T; Kettunen MI; Pulkkanen KJ; Kauppinen R; Jackson DG; Kubo H; Nishikawa S; Ylä-Herttuala S; Alitalo K
Nat Med; 2001 Feb; 7(2):199-205. PubMed ID: 11175851
[TBL] [Abstract][Full Text] [Related]
38. Functional Importance of a Proteoglycan Coreceptor in Pathologic Lymphangiogenesis.
Johns SC; Yin X; Jeltsch M; Bishop JR; Schuksz M; El Ghazal R; Wilcox-Adelman SA; Alitalo K; Fuster MM
Circ Res; 2016 Jul; 119(2):210-21. PubMed ID: 27225479
[TBL] [Abstract][Full Text] [Related]
39. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats.
Krishnan J; Kirkin V; Steffen A; Hegen M; Weih D; Tomarev S; Wilting J; Sleeman JP
Cancer Res; 2003 Feb; 63(3):713-22. PubMed ID: 12566318
[TBL] [Abstract][Full Text] [Related]
40. Lymphangiogenesis, inflammation and metastasis.
Schoppmann SF
Anticancer Res; 2005; 25(6C):4503-11. PubMed ID: 16334134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
